<PAGE>


Exhibit 99.6


          MIV THERAPEUTICS INC. LISTED ON THE FRANKFURT STOCK EXCHANGE

MIV Therapeutics Inc. (MIVT.OB:OTC BB) is pleased to announce the Company's
listing application has met all admission requirements and its Regulation S
stock has been accepted for listing on the Frankfurt Stock Exchange (Frankfurt
WKN: 911285, MIV1.FSE ). MIVT will continue to trade on the NASDAQ OTC Bulletin
Board.

Mr. Alan Lindsay, Chairman, President and CEO of MIV Therapeutics stated, "The
Frankfurt Exchange has the highest transparency standards in Europe and is one
of the world's largest trading centres for securities. This increases our
exposure to a Pan-European platform and opens the door wider to institutional
interest in our Company and its technology.

Mr. Lindsay added, "We recognize the importance of the European Community where
we have already established an awareness of MIV Therapeutics Inc. MIVT was
recently profiled on Prime-Time EuroNews TV and had Swiss independent research
analysis coverage initiated last month."

MIVT recently announced significant milestones. The first was the success of an
independent animal trial of its unique hydroxyapatite (HAp) stent coating. The
trial, "Thrombogenicity Assay in Dogs", was performed by the Toxikon Corporation
in Bedford, Massachusetts to evaluate blood-clotting. When blood contacts
biological foreign material it triggers blood platelet activation that can
eventually lead to thrombosis (blood-clotting). These clots can result in the
blockage of vessels at the implant location or be released into the patient's
blood stream, where they can obstruct distant blood vessels, potentially leading
to strokes or even death. On Sept 24, MIVT announced the achievements of its
government assisted Research & Development program. "Functionally Gradient
Calcium Phosphate Coatings for Stents".

ABOUT MIV THERAPEUTICS

MIV Therapeutics is developing a new generation of biocompatible stent coatings
and drug-delivery technologies using HAp non-polymer technology. The Company's
business objective is to be a leader in coating technologies and drug-delivery
devices for both cardiovascular and non-vascular disorders.

MIV's manufacturing facility maintains a comprehensive QA (Quality Assurance)
system which meets the guidelines of ISO 9001 (1994) and ISO 13485 (1996)
requirements, complies with applicable FDA guidelines and GMP requirements. MIV
has also developed a line of proprietary coronary stents and is capable of
private label manufacturing and out-sourcing.

Please visit the www.mivtherapeutics.com website for further information on the
milestones listed above and for access to English and German versions of the
SISM research report.

 Daniel Byrne
 Investor Relations
 dbyrne@mivtherapeutics.com
 (888) 998-8886

 Product inquiries and business opportunities:
 Arc Rajtar
 arajtar@mivi.ca
(604) 301-9545 ext 22

EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE MATTERS DISCUSSED IN
THIS PRESS RELEASE ARE FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS ARE INDICATED
BY WORDS OR PHRASES SUCH AS "IMPORTANCE", "MILESTONES", "SIGNIFICANT",
"SUCCESS", "NEW GENERATION", "ACHIEVEMENTS" AND "UNIQUE". THESE STATEMENTS ARE
MADE UNDER "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE DESCRIBED IN
FORWARD-LOOKING STATEMENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES. SEE THE
COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION INCLUDING, WITHOUT
LIMITATION, THE COMPANY'S RECENT FORM 10-K AND FORM 10-QS, WHICH IDENTIFY
SPECIFIC FACTORS THAT MAY CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY
FROM THOSE DESCRIBED IN THE FORWARD-LOOKING STATEMENTS.